Lifeboat Foundation

The risk of getting dementia may go up as you get older if you don’t get enough slow-wave sleep. Over-60s are 27 percent more likely to develop dementia if they lose just 1 percent of this deep sleep each year, a 2023 study found.

Slow-wave sleep is the third stage of a human 90-minute sleep cycle, lasting about 20–40 minutes. It’s the most restful stage, where brain waves and heart rate slow and blood pressure drops.

Deep sleep strengthens our muscles, bones, and immune system, and prepares our brains to absorb more information. Recently, research discovered that individuals with Alzheimer’s-related changes in their brain did better on memory tests when they got more slow-wave sleep.

Using functional magnetic resonance imaging (fMRI) data, the research team identified 24 networks with different functions,…

MIT researchers created the most comprehensive map yet of the functions of the brain’s cerebral cortex. Using fMRI, the team identified 24 networks with different functions, which include processing language, social interactions, visual features, and other sensory input.

A published today https://nature.com/articles/s41586-024-08145-x reveals brain cells can form a coordinate system for our behaviours.

Mice generalize complex task structures by using neurons in the medial frontal cortex that encode progress to task goals and embed behavioural sequences.

A study presents battery-free, polymer-based wearable devices that wrap around neurons, allowing for real-time monitoring and modulation of cellular activity. This innovation aims to restore neuronal function in conditions like multiple sclerosis.

This development comes from…

Researchers have designed a high-speed 3D bioprinter to accurately print human tissues.

Continue reading “New high-speed 3D bioprinter uses acoustics to print human tissues” »

MIT researchers have developed a battery-free, subcellular-sized device made of polymer designed to measure and modulate a neuron’s electrical and metabolic activity. When the device is activated by light, it can gently wrap around the neuron cell’s axons and dendrites without damaging the cells.

Scientists want to inject thousands of these tiny wireless devices into a patient’s central nervous system and then actuate them noninvasively using light. The light would penetrate the tissue and allow precise control of the devices, and thereby restore function in cases of neuronal degradation like multiple sclerosis (MS).

The MIT researchers developed these thin-film devices from a azobenzene, a soft polymer that readily reacts to light. Thin sheets of azobenzene roll into a cylinder when exposed to light, which enables them to wrap around cells. Researchers can control the direction and diameter of the rolling by changing the intensity and polarization of the light, producing a microtube with a diameter smaller than one micrometer.

Ionut Constantinescu, Tiago Pimentel, Ryan Cotterell, Alex Warstadt ETH Zurich 2024 https://arxiv.org/abs/2407.

Children are better at learning a…

We’ve detected that JavaScript is disabled in this browser. Please enable JavaScript or switch to a supported browser to continue using x.com. You can see a list of supported browsers in our Help Center.

Continue reading “Investigating Critical Period Effects in Language Acquisition through Neural Language Models” »

The intricate relationship between hydrogen sulfide (H2S), gut microbiota, and sirtuins (SIRTs) can be seen as a paradigm axis in maintaining cellular homeostasis, modulating oxidative stress, and promoting mitochondrial health, which together play a pivotal role in aging and neurodegenerative diseases. H2S, a gasotransmitter synthesized endogenously and by specific gut microbiota, acts as a potent modulator of mitochondrial function and oxidative stress, protecting against cellular damage. Through sulfate-reducing bacteria, gut microbiota influences systemic H2S levels, creating a link between gut health and metabolic processes. Dysbiosis, or an imbalance in microbial populations, can alter H2S production, impair mitochondrial function, increase oxidative stress, and heighten inflammation, all contributing factors in neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

The small-scale FDA-cleared trial is designed to evaluate both the safety and initial efficacy of RB-ADSCs in nine patients with Alzheimer’s. Regeneration Biomedical’s CTAD presentation focused on the first three enrolled patients, who each received a single dose of RB-ADSCs delivered directly into the lateral ventricles of the brain using an “Ommaya reservoir” – a device implanted under the scalp to bypass the blood-brain barrier, a major obstacle in Alzheimer’s treatments.

Biomarker analysis at the 12-week mark demonstrated reductions in both p-Tau and amyloid-beta – two proteins strongly associated with Alzheimer’s disease progression. In cerebrospinal fluid (CSF) samples from the three patients, p-Tau levels decreased to “normal” levels, while amyloid PET scans also showed a reduction in amyloid buildup.

Regeneration Biomedical also reported its treatment produced signs of cognitive improvement, with two of the three patients showing increased Mini-Mental State Examination (MMSE) scores, a common measure of cognitive function.